Federico Wintour

Chief Executive Officer


Federico Wintour is Chief Executive Officer at GBT. He has over thirty years of experience in the Latin America pharmaceutical market, where he worked in leading and very well know multinational pharmaceutical companies in many countries across Latam. 

Prior to joining GBT, Mr. Wintour worked at Vifor Pharma where he successfully managed the Latin America region, where he managed more than twenty countries and around fifty partners and distributors, for almost eight years. 

Previously, Federico spent fourteen years with Merck Sharp & Dohme (MSD), one of the world’s largest research based pharmaceutical companies, where he served in multiple roles and various countries. During his time at MSD, he was Regional Managing Director for the Southern Cone Region (Argentina, Bolivia, Chile, Paraguay, Peru and Uruguay), Managing Director for Colombia, and earlier Managing Director for Ecuador too. He was also Regional Marketing Director for the Candean Region (Central America and Andean countries), and Business Planning Director and Business Development Director for Argentina as well. Earlier in his career, he held positions at Serono, a Swiss biotech company, which was later acquired by Merck.

Mr. Wintour holds a degree in Economics from the Universidad de Buenos Aires and a master’s degree in Management and Strategic Marketing from the Universidad de Ciencias Empresariales y Sociales in Argentina. Federico will be based in the company’s headquarters in Montevideo, Uruguay.

Raquel Balsa

Chief Financial Officer


Raquel Balsa is Chief Financial Officer for GBT. She brings to the team more than 20 years of experience in international accounting, finance and taxes.

An Uruguayan by birth, Raquel developed a broad two-decade career at PricewaterhouseCoopers, spanning areas like audit, accounting, international trade, transfer pricing and taxes, consulting with some of the largest players in the region.

Mrs. Balsa is a Certified Public Accountant by Universidad de la República in Uruguay.

Renato De Giorgi

EVP, Business Development


Mr. De Giorgi joined GBT in 2015 as EVP, Business Development. In this role, he oversees the company´s business development activities, including mergers, acquisitions and licensing activities.

Mr. De Giorgi is an executive with years of experience in business development in global markets, including the U.S., Europe and emerging markets. His expertise is in Latin American markets.

Before joining GBT, he served as Chief Executive Officer of Droguería del Sud, the largest Argentinean Pharmaceutical Wholesaler. Prior to this role, he worked at Bausch + Lomb as the Regional Business Development Director for Latin America, based in Sao Paulo, Brazil.

Mr. De Giorgi also served for more than 15 years at GE, Booz & Company and Toyota, occupying different business development positions of increasing responsibility within Latin American and European markets.

Mr. De Giorgi pursued industrial engineering studies at Instituto Tecnológico de Buenos Aires and holds an MBA from Harvard Business School.

Román Saglio

EVP, Marketing


Mr. Saglio joined GBT in 2015 as EVP, Marketing. He is responsible for marketing activities, partnership and strategic alliances management.

Mr. Saglio is a marketing and sales pharmaceutical executive with more than 20 years of experience in Europe, the U.S., and emerging markets. He has regional expertise in Latin America.

Prior to joining GBT, Mr. Saglio was Sr. Marketing Director, Retina US at Bausch + Lomb. Formerly he was the Latin American Regional Director, where he was responsible for building the region´s pharmaceutical business.

Formerly Mr. Saglio served for more than 15 years at Schering-Plough and Merck & Co, occupying different sales and marketing positions of increasing responsibility within Latin American and European markets.

Mr. Saglio is a native of Argentina, where he pursued pharmaceutical studies at Universidad de Buenos Aires. He holds an MBA from the Universidad Argentina de la Empresa (UADE).

Julieta Serna

EVP, Latam


Ms. Serna joined Grupo Biotoscana in 2016 as Executive Vice President Strategy and on October 2017 was announced as Executive Vice President for the Andean Region. Prior to joining GBT, Ms. Serna was the Procurement and Business Intelligence Director at LKM, where she also held the position of Controller. Previously, Ms. Serna was an executive with Advent International, focusing on M&A opportunities within Argentina, Uruguay and Chile. Ms. Serna pursued commercial business economics studies at Universidad Torcuato Di Tella (UTDT). She holds a Master in Finance from the Universidad Torcuato Di Tella

Ivan French

EVP, Research & Development


Ivan French is Executive Vice-President of Research and Development at GBT, since December 2017. In his role, Ivan leads GBT´s proprietary products development efforts, taking over the company´s research center in Argentina and its recently acquired DOSA research center. Together with Renato De Giorgi, head of Business Development and Daniel Flores, Sr. Science Advisor, Ivan leads the company’s pipeline strategy.

Ivan French has a long career combining medicine and management, having been for example a Medical Team Leader at Medicines sans Frontiers, a clinical research fellow at Genzyme Corporation but also an investment banker with Morgan Stanley New York and most recently, the General Manager for Uber Uruguay.

Ivan French has a Medical Doctor Degree (Magna cum Laude) from Universidad Austral and an MBA from Harvard Business School.

Daniel Flores

Sr. Advisor, Science


Dr. Flores serves as Sr. Advisor Science for GBT since 2015. In his role, Dr. Flores acts as chief advisor on all science and medical matters, providing critical support in the understanding of science evolution paths, evaluation of novel technologies and global R&D trends.

Prior to joining GBT, Dr. Flores served as Medical Director LATAM region at Eli Lilly for almost 20 years.

Dr. Flores resided for many years in US, where he was Associated Investigator and Faculty member of Medical School at University of Pennsylvania. He is also a prolific investigator, with more than 40 international publications, including rare disease and oxygen toxicity.

Dr. Flores is a native of Argentina and graduated as Medical Doctor from University of Buenos Aires.